Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials

Hypertension

Volumn 49, Issue 4, 2007, Pages 792-798

  Strazzullo, Pasquale ^a   Kerry, Sally M ^b   Barbato, Antonio ^a   Versiero, Marco ^a   D'Elia, Lanfranco ^a   Cappuccio, Francesco P ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Blood pressure; Drug therapy; Hypercholesterolemia; Hypertension, arterial; Meta analysis; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CERIVASTATIN; CHLORTALIDONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; FLUVASTATIN PLUS ORLISTAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; NITRIC OXIDE; PLACEBO; PRAVASTATIN; PROBUCOL; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TETRAHYDROLIPSTATIN;

ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; DIASTOLE; DRUG EFFECT; PATHOPHYSIOLOGY; SYSTOLE;

BLOOD PRESSURE; DIASTOLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; SYSTOLE;

EID: 34047238791     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000259737.43916.42     Document Type: Article

References (52)

1. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38:1581-1583.
2. Walley T, Folino-Gallo P, Schwabe U, van Ganse E, EuroMedStat group. Variations and increase in use of statins across Europe: data from administrative databases. BMJ. 2004;328:385-386.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-732.
4. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725-730.
5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:III39-III43.
6. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068.
7. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19:540-556.
8. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A; Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J. 2004;148:285-292.
9. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y, Gomi T, Moriya H, Kobayashi S. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens. 2004;17:502-506.
10. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286.
11. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: results from the UCSD Statin Study (abstract). Circulation. 2004;110:402.
12. Dahlof B, Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA) (abstract). Circulation. 2004;110:402.
13. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arteroscler Thromb Vasc Biol. 2003;23:729-736.
14. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hyper-cholesterolemic men. Circulation. 1999;100:2131-2134.
15. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis. 2001;155:245-250.
16. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39:1020-1025.
17. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, Rila H, Hoogendam I, Van Bortel L. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol. 1995;48:217-223.
18. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs Lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502-510.
19. Hommel E, Andersen P, Gall MA, Nielsen F, Jensen B, Rossing P, Dyerberg J, Parving HH. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447-451.
20. McDowell IF, Smye M, Trinick T, Shortt JA, Archibald MP, Trimble ER, Nicholls DP. Simvastatin in severe hypercholesterolaemia: a placebo controlled trial. Br J Clin Pharmac. 1991;31:340-343.
21. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2α formation. J Cardiovasc Pharmacol. 2002;40:868-874.
22. O'Callaghan CJ, Krum H, Conway EL, Lam W, Skiba MA, Howes LG, Louis WJ. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Pressure. 1994;3:404-406.
23. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol. 1995;75:582-586.
24. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20:1891-1895.
25. Bak AA, Huizer J, Leijten PA, Rila H, Grobbee DE. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. J Intern Med. 1998;244:371-378.
26. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, doubleblind, placebo-controlled comparison of the action of orlistat, fluvastatin or both, on anthropometric measurements, blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther. 2003;25:1107-1122.
27. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001;21:449-454.
28. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687-3692.
29. Fogari R, Derosa G, Lazzari P, Zoppi A, Fogari E, Rinaldi A, Mugellini A. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens. 2004;17:823-827.
30. Balletshofer BM, Goebbel S, Rittig K, Enderle M, Schmolzer I, Wascher TC, Ferenc Pap A, Westermeier T, Petzinna D, Matthaei S, Haring HU. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes - a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes. 2005;113:324-330.
31. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults from 61 prospective studies. Lancet. 2002;360:1903-1913.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
33. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320:1574-1577.
34. de Divitiis M, Rubba P, Di Somma S, Liguori V, Galderisi M, Montefusco S, Carreras G, Greco V, Carotenuto A, Iannuzzo G, de Divitiis O. Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol. 1996;1:78:763-768.
35. Fleischmann EH, Schlaich MP, Schmidt BM, Oehmer S, Schmieder RE. Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics. Nephrol Dial Transplant. 2002;17:1758-1765.
36. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
37. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
38. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002;105:933-938.
39. Kalinowski L, Dobrucki LW, Malinski T. Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol. 2002;53:585-595.
40. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T. The effect of statins on mRNA levels of genes related to inflammation, coagulation and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb. 2002;9:177-183.
41. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new -CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res. 2002;942:23-30.
42. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res. 2000;87:526-528.
43. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
44. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.
45. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117-2121.
46. Asberg A, Hartmann A, Fjeldsa E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant. 2001;16:1920-1924.
47. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000;36:617-621.
48. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischaemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233.
49. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethyloglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376-379.
50. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. Direct in vivo evidence of a vascular statin: a single dose cerivastatin increases vascular endothelial responsiveness in healthy normocholesterolaemic patients. Br J Pharmacol. 2002;54:395-399.
51. John S, Schneider MP, Delles C, Jacobi J, Schmeider RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149:473.
52. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154:87-96.